Accessibility evaluation and research on legal security system for orphan drugs in America and China on American and Chinese drugs for rare diseases

Chinese Pharmaceutical Journal

Volumn 46, Issue 14, 2011, Pages 1129-1132

  Ding, Jing Xi ^a   Sun, Xiao Dong ^a   Ji, Na ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHINESE DRUG; ORPHAN DRUG;

ARTICLE; CHINA; EVALUATION; LEGAL ASPECT; RARE DISEASE; RESEARCH; UNITED STATES;

EID: 84860394798     PISSN: 10012494     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. GONG S W, ZHANG M, DENG X L, et al. Ideas on the definition of rare disease and orphan drugs in China [J]. Chin J New Drugs, 2006,15(15):1225-1229.
2. TAO Y. The current situation of orphan drug regulation in the United States[J]. Chin Pharm J, 2001,36(9):634-636.
3. GUAN X D, SHI L W. Analysis on the establishment of national drug policy in China[J]. Chin Pharm J, 2009,44(2):158-160.
4. LI H T. Analysis on the accessibility of drugs in China [J]. Chin Health Serv Management, 2009(9):612-614.
5. FENG J H. Public health crisis, accessibility of drugs and its parallel imports [J]. National Judges College Law J, 2004,12(25):15-18.
6. GONG S W. Study of Management Strategies of Improving Access to Orphan Drugs in China [D]. Wuhan: Huazhong Univeristy of Science and technology 2008. 1-122.
7. YANG C L. Incidence survey of leukemia in china [J]. Acta Acad Med Sin, 1992,14(1):12-19.
8. LL S. Facts 2010-2011 [J/OL]. New York: LLS, 2011 : [2011-05-16]. http://www.lls.org/content/nationalcontent/resource-center/ freeeducationmaterials/generalcancer/pdf/facts.
9. MOHC. Year Book of Health in the People's Republic of China [DB/OL] . Beijing: peking union medical college press, 2010 [2011-05-16]. http://www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ptjnj/year2010/ index2010.html.
10. US. Census Bureau. Statistical Abstract of the United States: 2007 [DB/OL]. New York: U.S. Census Bureau, 2007 [2011-05-16]. http://www.census.gov/ prod/www/statistical-abstract-us.html.
11. FDA. FDA Application Search Orphan Drug Designations and Approvals[DB/OL]. New York: FDA, 2011 [2011-05-16] http://www.accessdata.fda. gov/scripts/opdlisting/oopd/index.cfm.
12. SFDA. Data Search [DB/OL]. Beijing: SFDA, 2011 [2011-05-16]. http://appl.sfda.gov.cn/datasearch/face3/dir.html.
13. ZHANG R W, HU S L. A comparative study of international price for pharmaceuti-cals medicine price [J]. Chin Health Econ, 2001,20(2):26-28.
14. VILLA S, COMPAGNI A, REICH M R. Orphan drug legislation: lessons for neglected tropical diseases [J]. Int J Health Plann Mgmt, 2009,24(3):27-42.
15. SFDA The Southern Institute of Medical Economics. Database [DB/OL]. GuangDong:The Southern Institute of Medical Economics, 2011 [2011 -05-16]. http://www.meinet.com.cn:8080/Query/MedicinePrice/.
16. RxUSA Pharmacy. Database [DB/OL]. New York: RxUSA, 2011 [2011-05-16]. http://www.rxusa.com/.
17. ZHANG J G. A background and present situation of USA orphan drug[J]. Chin J Pharmacoepiolemiol, 2002(3):153-154.
18. DING J X, ZHAO M. The comparative study on supervision and incentive policies of Sino-US during the innovative drug R&D [J]. Chin J New Drugs, 2009,18(5):387-392.
19. ZHAO C X, XU F, WANG Y, et al. Ideas on the strategy in establishing orphan drug managing system [J]. Med Philosophy, 2003,24(7):41-43.